Biostat 215 Discussion #1 Thomas B. Newman, MD, MPH with thanks to Gabriel Escobar, MD; Michael Kuzniewicz, MD, MPH, Chuck, Eric and Steve)

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Apr-15H.S.1 Stata: Linear Regression Stata 3, linear regression Hein Stigum Presentation, data and programs at: courses.
Exploring the Shape of the Dose-Response Function.
Controlling for Time Dependent Confounding Using Marginal Structural Models in the Case of a Continuous Treatment O Wang 1, T McMullan 2 1 Amgen, Thousand.
A workshop introducing doubly robust estimation of treatment effects
Dallas 2015 TFQO: Marya Strand, MD, MS; COI#222 EVREV 1: Marya Strand, MD, MS; COI#222 EVREV 1: Takahiro Sugiura, MD; COI#224 Taskforce: NLS Umbilical.
Neonatal Jaundice By Dr. Nahed Al-Nagger
Douglas Almond Joseph J. Doyle, Jr. Amanda E. Kowalski Heidi Williams
AAP Clinical Practice Guideline AAP Subcommittee on Hyperbilirubinemia. Pediatrics. 2004;114:297–316 Copyright © 2003, Rev 2005 American Academy of Pediatrics.
Mickey Lynch, Jimmy Mulvey, and Brenda Palma
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Total Serum Bilirubin Levels at or Above the ETT Wu YW, Kuzniewicz MW, Wickremasinghe.
Clustered or Multilevel Data
Alternatives to Randomized Trials for Determining Treatment Efficacy (or Harm) Thomas B. Newman, MD, MPH.
Jul-15H.S.1 Linear Regression Hein Stigum Presentation, data and programs at:
BIOST 536 Lecture 2 1 Lecture 2 - Modeling Need to find a model that relates the outcome to the covariates in a meaningful way  Simplification of the.
A Longitudinal Study of Maternal Smoking During Pregnancy and Child Height Author 1 Author 2 Author 3.
Correlation and Regression Analysis
Universal Predischarge Screening for Neonatal Hyperbilirubinemia Report from Evidence Review Secretary's Advisory Committee on Heritable Disorders in Newborns.
Covariate Selection for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
 The yellowing of the skin and eyes due to the build up of bilirubin in the blood stream.  Bilirubin is produced during the breakdown of RBCs in the.
1 Clerk Meeting Case presentation 範例 簡單扼要的討論 Slides 不要太多.
Good Morning! July 19, Semantic Qualifiers Symptoms Acute /subacuteChronic LocalizedDiffuse SingleMultiple StaticProgressive ConstantIntermittent.
Logistic Regression. Outline Review of simple and multiple regressionReview of simple and multiple regression Simple Logistic RegressionSimple Logistic.
Maternity Center presentation Vision: Delivering Patient -Family-Centered Maternity Care through a caring team.
Advanced Statistics for Interventional Cardiologists.
Alternatives to Randomized Trials for Estimating Treatment Efficacy (or Harm) Thomas B. Newman, MD, MPH Professor of Epidemiology and Biostatistics and.
Neonatal Jaundice Hyperbilirubinemia Fred Hill, MA, RRT.
Alternatives to Randomized Trials for Estimating Treatment Efficacy (or Harm) Thomas B. Newman, MD, MPH Professor of Epidemiology and Biostatistics and.
FPP Chapters Design of Experiments. Main topics Designed experiments Comparison Randomization Observational studies “control” Compare and contrast.
The Influence of Primary Care Practice Climate on Medical Services Costs and Quality of Care Roblin DW 1, Howard DH 2, Becker ER 2, Adams EK 2, Greenfield.
Introduction to Clinical Research and Research Questions Thomas B. Newman, MD,MPH Professor of Epidemiology & Biostatistics and Pediatrics, UCSF Epi ,
Early Parental Satisfaction with Pediatric Care: Does it Improve Immunization of Young Children? Ashley Schempf BS, Cynthia Minkovitz MD MPP Donna Strobino.
Biostat 215 Clarifying the Causal Question Thomas B. Newman, MD, MPH.
October 15H.S.1 Causal inference Hein Stigum Presentation, data and programs at:
Quality Education for a Healthier Scotland Multidisciplinary Neonatal Jaundice Promoting multiprofessional education and development in Scottish maternity.
Insert Program or Hospital Logo Introduction Transcutaneous Bilirubinometry in Preterm Infants During and After Phototherapy Sadia Ansari MD *, Mike Malloy.
Introduction to Clinical Research and Research Questions Thomas B. Newman, MD,MPH Professor of Epidemiology & Biostatistics and Pediatrics, UCSF Epi ,
Hyperbilirubinemia Neonatal Hyperbilirubinemia. Jaundice Yellow discoloration of skin due to elevated serum bilirubin level > 5mg/dl in neonates > 2 mg/dl.
Introduction to Clinical Research and Research Questions Thomas B. Newman, MD,MPH Professor of Epidemiology & Biostatistics and Pediatrics, UCSF Epi ,
Alternatives to Randomized Trials for Estimating Treatment Efficacy (or Harm) Thomas B. Newman, MD, MPH Professor of Epidemiology and Biostatistics and.
Elegant Alternatives to Randomized Trials for Determining Treatment Efficacy (or Harm) Thomas B. Newman, MD, MPH Professor of Epidemiology and Biostatistics.
Alternatives to Randomized Trials for Estimating Treatment Efficacy (or Harm) Thomas B. Newman, MD, MPH Professor of Epidemiology and Biostatistics and.
Henry Domenico Vanderbilt University Medical Center.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Alternatives and Enhancements to Intention to Treat Analyses of Randomized Trials Thomas B. Newman, MD, MPH February 20, 2002.
Evaluating Risk Adjustment Models Andy Bindman MD Department of Medicine, Epidemiology and Biostatistics.
INDIANA UNIVERSITY BLOOMINGTON D.T. Dibaba MPH, S. Horbal MPH, M. A. Sayegh PhD, MPH Indiana University School of Public Health- Bloomington Department.
Effects of breastfeeding on outpatient visits and hospitalizations during the first 18 months of life in Hong Kong Chinese infants Leung GM, Ho LM, Lam.
POPLHLTH 304 Regression (modelling) in Epidemiology Simon Thornley (Slides adapted from Assoc. Prof. Roger Marshall)
Exact Logistic Regression
1 Ordinal Models. 2 Estimating gender-specific LLCA with repeated ordinal data Examining the effect of time invariant covariates on class membership The.
Birthweight (gms) BPDNProp Total BPD (Bronchopulmonary Dysplasia) by birth weight Proportion.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Effect of Laboratory Calibration of Neonatal Bilirubin Kuzniewicz MW, Greene DN,
NEONATAL JAUNDICE DR NADEEM ALAM ZUBAIRI MBBS, MCPS, FCPS Consultant Neonatologist / Paediatrician.
Implementation of a Flowsheet to Better Manage Bilirubin Levels in Newborns Dr. Alia Chauhan, MD, FAAP Assistant Professor of Pediatrics & Family Medicine.
Copyright © 2017 American Academy of Pediatrics.
Sarah M. Coors, DO1, PGY-6, Joseph L. Hagan, ScD1, Joshua J
Neonatal Hemolytic Jaundice
Chapter 36 Hemolytic Disorders.
Logistic Regression APKC – STATS AFAC (2016).
Copyright © 2017 American Academy of Pediatrics.
Guidelines for phototherapy in hospitalized infants of 35 or more weeks' gestation. These guidelines are based on limited evidence and levels shown are.
Blood Exchange Transfusion
Guidelines for phototherapy in hospitalized infants of 35 or more weeks’ gestation.Note: These guidelines are based on limited evidence and the levels.
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Standard Statistical analysis Linear-, logistic- and Cox-regression
Guidelines for phototherapy in hospitalized infants of 35 or more weeks’ gestation.Note: These guidelines are based on limited evidence and the levels.
Counterfactual models Time dependent confounding
Chapter 3 Hernán & Robins Observational Studies
Guidelines for exchange transfusion in infants 35 or more weeks’ gestation.Note that these suggested levels represent a consensus of most of the committee.
Presentation transcript:

Biostat 215 Discussion #1 Thomas B. Newman, MD, MPH with thanks to Gabriel Escobar, MD; Michael Kuzniewicz, MD, MPH, Chuck, Eric and Steve)

Outline n Background about jaundice and phototherapy n Discussion/Review of some key topics –Potential and counterfactual outcomes –Underlying assumptions –Causal model statements as if/then statements

Background for phototherapy dataset n Bilirubin: Yellow breakdown product of heme n Jaundice: Yellow color due to high bilirubin. n DAT: Direct Antiglobulin (“Coombs”) Test: measures maternal antibodies on infant red cells, a cause of jaundice n Phototherapy: Shining light on the babies skin -- helps lower bilirubin levels n Exchange transfusion: replace baby’s blood with donor blood – more drastic treatment to lower bilirubin levels n Kernicterus: Permanent brain damage (cerebral palsy, deafness) from very high bilirubin levels (and other illness)

Background -2 n 2/3 of newborns develop jaundice n 5-15% in Northern CA Kaiser hospitals are treated with phototherapy (PT) n Current treatment thresholds higher than used in previous trials n No randomized trials of PT as currently recommended

AAP Phototherapy Guidelines

AAP Exchange Transfusion Guidelines

NNT paper title n Research Questions n For newborns with total serum bilirubin (TSB) levels close to those at which the AAP recommends phototherapy –What is the efficacy of phototherapy? –What is the number needed to treat (NNT)? –What factors affect the NNT?

Methods n Design: Historical cohort study using electronically available data n Setting: 12 Northern California Kaiser Permanente Medical Care Program hospitals, n Subjects eligible if ≥ 2000 g, ≥ 35 weeks gestation and qualifying TSB level ± 3 mg/dL from AAP phototherapy threshold (PTT) (N=22,547)

“Qualifying” TSB levels

Qualifying TSB levels and key confounder TSB - PTT = + 3 mg/dL TSB - PTT = -2 mg/dL

Qualifying TSB levels and key confounder In phototherapy.dta this variable is called qual_TSB and is coded as follows: Qualifying TSB – PT Threshold (mg/dL) 1-3 to < to < to <0 40 to <1 51 to <2 62 to <3

Methods, cont'd n Intervention: hospital phototherapy within 8 hours of the qualifying TSB (“phototherapy”) n Covariates: age, birth weight, gestational age, hospital of birth, sex, qual_TSB (6 categories), year of birth

Outcome variable n Crossing the AAP exchange transfusion threshold within 48 hours of the qualifying TSB = “over_thresh” n Rationale –Incorporates age and AAP risk group –If ET threshold crossed after 48 hours, initial decision not to do PT probably reasonable

TSB levels  AAP Exchange level

Questions?

Possible discussion questions -1 n What do we mean my potential outcomes and counterfactual outcomes? n Potential outcome estimation is deterministic, but the world isn’t. Is this a problem? n Why is potential outcome estimation like a missing data problem? What does it have to do with imputation?

Possible discussion questions -2 n What is the “positivity” assumption? (Also called the “experimental treatment assumption” = ETA). n What is the “randomization” assumption? n Why should estimates from causal models be considered if…then statements? n Other questions?

Splines -1 n Want to relate a continuous predictor to an outcome n Not reasonable to assume relationship is linear n What to do? n Example: relationship between birth weight and outcome (“over_thresh”) in PT dataset

Switch to Stata

lowess over_thresh birth_wt, logit

Stata code *Biostat 215 Discussion #1 use "/Users/thomasnewman/Documents/TEACH/BIOSTAT/Biostat 215 Causal modeling MSMs DAGs etc/Stata and labs/phototherapy.dta" tab birth_wt logistic over_thresh birth_wt estat gof, group(10) tab * Logistic model fits poorly tabu bwcat over_thresh, row chi * Can use indicator variables logistic over_thresh i.bwcat * What will estat gof show? estat gof, group(10) tab * Indicator variables lead to discontinuity at cutoffs. * Demonstrate REGULAR splines mkspline bwsp 5 = birth_wt, di scatter bwsp1 birth_wt scatter bwsp2 birth_wt scatter bwsp3 birth_wt scatter bwsp4 birth_wt ggen junk = bwsp1+ bwsp2+ bwsp3+ bwsp4+ bwsp5 regress birth_wt junk logistic over bwsp* * Contrast with RESTRICTED CUBIC SPLINES mkspline bwsp = birth_wt, cubic scatter bwsp1 birth_wt scatter bwsp2 birth_wt scatter bwsp3 birth_wt scatter bwsp4 birth_wt logistic over bwsp* **Alternatively, include quadratic term sum birth_wt ggen bw2=(birth_wt-3.324)^2 logistic over birth_wt bw2 estat gof, group(10) tab